These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2784018

  • 1. Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.
    Marumo K, Muraki J, Ueno M, Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H.
    Urology; 1989 Mar; 33(3):219-25. PubMed ID: 2784018
    [Abstract] [Full Text] [Related]

  • 2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.
    Cancer; 1993 Sep 01; 72(5):1733-42. PubMed ID: 8348502
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application.
    Marumo K, Ueno M, Muraki J, Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H.
    Urol Int; 1991 Sep 01; 47 Suppl 1():132-7. PubMed ID: 1949370
    [Abstract] [Full Text] [Related]

  • 4. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH.
    J Clin Oncol; 1992 Feb 01; 10(2):275-81. PubMed ID: 1732429
    [Abstract] [Full Text] [Related]

  • 5. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Nat Immun; 1992 Feb 01; 11(3):133-43. PubMed ID: 1392401
    [Abstract] [Full Text] [Related]

  • 6. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
    Janssen RA, Buter J, Straatsma E, Heijn AA, Sleijfer DT, de Vries EG, Mulder NH, The TH, de Leij L.
    Cancer Immunol Immunother; 1993 Feb 01; 36(3):198-204. PubMed ID: 8439981
    [Abstract] [Full Text] [Related]

  • 7. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R, Trentin L, Cerutti A, Enthammer C, Milani A, Franceschi T, Messina C, Cetto GL, Agostini C, Semenzato G.
    Cancer; 1994 Nov 01; 74(9):2562-9. PubMed ID: 7522954
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M.
    Cancer Res; 1990 Oct 15; 50(20):6708-15. PubMed ID: 2208137
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K, Tazaki H.
    Prog Clin Biol Res; 1990 Oct 15; 350():263-73. PubMed ID: 2117286
    [No Abstract] [Full Text] [Related]

  • 11. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
    Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA.
    Ann Intern Med; 1988 Apr 15; 108(4):518-23. PubMed ID: 3258138
    [Abstract] [Full Text] [Related]

  • 12. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L, Fanti G, Bongiovanni C, Goldoni M, Alberici F, Bonomini S, Cristinelli L, Buzio C.
    Med Oncol; 2009 Apr 15; 26(1):38-44. PubMed ID: 18516705
    [Abstract] [Full Text] [Related]

  • 13. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A, Muul LM, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):206-14. PubMed ID: 3257161
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
    Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graaf WT, The TH, de Leij L, Mulder NH.
    Br J Cancer; 1994 Oct 01; 70(4):652-61. PubMed ID: 7917912
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T.
    J Biol Response Mod; 1990 Apr 01; 9(2):167-77. PubMed ID: 1971303
    [Abstract] [Full Text] [Related]

  • 18. [Anti-tumor effects of interleukin 2 against genitourinary cancer--basic study and clinical application].
    Marumo K.
    Hum Cell; 1988 Mar 01; 1(1):65-70. PubMed ID: 3154016
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunologic effects of recombinant interferon-gamma in patients with renal cell carcinoma.
    Marumo K, Murai M, Deguchi N, Ikeuchi K, Tazaki H.
    Keio J Med; 1990 Jun 01; 39(2):97-101. PubMed ID: 2120502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.